Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.
Most patients with advanced breast cancer develop osteolytic bone metastases, which have numerous complications. Because current therapies are not curative, new treatments are needed. Conditionally replicating adenoviruses (CRAds) are anticancer agents designed to infect and lyse tumor cells. However, in spite of their promise as selective cancer therapeutics, replicating adenoviruses have shown limited efficacy in the clinical setting. We hypothesized that a CRAd armed with osteoprotegerin (OPG) would eradicate bone metastases of breast cancer both directly, by oncolysis, and indirectly, by inhibiting osteoclastic bone resorption, and thus reducing the tumor burden. We constructed an armed CRAd (Ad5-Δ24-sOPG-Fc-RGD) by replacing viral E3B genes with a fusion of the ligand-binding domains of OPG and the Fc portion of human IgG1. Conditional replication was conferred by a 24-base pair deletion within E1A (Δ24), which prevents the binding of E1A to the retinoblastoma tumor suppressor/cell cycle regulator protein and limits replication in normal cells. Enhanced infection of cells expressing low levels of the primary Ad5 receptor was conferred by incorporating an arginine-glycine-aspartic acid (RGD) peptide sequence into the fiber knob to mediate binding to α(v) integrins. After characterization of the armed CRAd, we demonstrated that infection of breast cancer cells by Ad5-Δ24-sOPG-Fc-RGD both killed the infected cells by oncolysis and inhibited the formation of osteoclasts in an in vitro co-culture model. In a murine model of osteolytic bone metastases of breast cancer, the CRAd armed with shortened OPG (sOPG)-Fc reduced tumor burden in the bone and inhibited osteoclast formation more effectively than an unarmed CRAd.
Cody
J J
JJ
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Rivera
A A
AA
Lyons
G R
GR
Yang
S W
SW
Wang
M
M
Sarver
D B
DB
Wang
D
D
Selander
K S
KS
Kuo
H-C
HC
Meleth
S
S
Feng
X
X
Siegal
G P
GP
Siegall
G P
GP
Douglas
J T
JT
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology / Q000556:secondary*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051379:Mice; D053244:Osteoprotegerin / Q000235:genetics* / Q000378:metabolism; D047368:Tumor Burden / Q000235:genetics; D014779:Virus Replication
D002352:Carrier Proteins; D053244:Osteoprotegerin; C029702:prolactin-binding protein
J Biol Chem. 1998 Jun 5;273(23):14363-7
9603945
Cancer Res. 2005 Sep 1;65(17):7682-90
16140935
Virology. 2004 Mar 1;320(1):121-34
15003868
Cancer Res. 2005 Nov 15;65(22):10154-8
16287998
J Clin Invest. 2000 May;105(9):1169-72
10791988
Nat Rev Cancer. 2002 Aug;2(8):584-93
12154351
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474
16034900
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5483-8
18391209
J Virol. 1996 Nov;70(11):7498-509
8892868
Bone. 2007 Feb;40(2):471-8
17092788
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1943-8
12576544
Cell. 1997 Apr 18;89(2):309-19
9108485
Cancer. 2003 Feb 1;97(3 Suppl):887-92
12548591
Cancer Res. 2002 Feb 15;62(4):1063-8
11861383
Clin Cancer Res. 2002 Nov;8(11):3348-59
12429621
Cancer Res. 2003 Jan 15;63(2):287-9
12543775
Oncogene. 2000 Jan 6;19(1):2-12
10644974
Cell Tissue Res. 2002 Mar;307(3):337-45
11904770
Cancer. 2003 Feb 1;97(3 Suppl):834-9
12548583
Oncologist. 2000;5(6):463-70
11110597
Clin Exp Metastasis. 2007;24(5):389-401
17541709
Nat Biotechnol. 2000 Jul;18(7):723-7
10888838
J Clin Invest. 2001 May;107(10):1235-44
11375413
Mol Ther. 2000 May;1(5 Pt 1):391-405
10933960
Clin Exp Metastasis. 2003;20(4):327-34
12856720
J Bone Miner Res. 2000 Jul;15(7):1337-45
10893682
Clin Exp Metastasis. 2004;21(2):119-28
15168729
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
2673568
J Virol. 1996 Apr;70(4):2296-306
8642656
Cancer Res. 2001 Jun 1;61(11):4432-6
11389072
J Bone Miner Res. 1987 Dec;2(6):595-610
3455637
Clin Exp Metastasis. 2004;21(6):543-52
15679052
Cell. 2008 Feb 8;132(3):397-409
18267072
Clin Cancer Res. 2001 Jun;7(6):1654-60
11410503
Nat Med. 2000 Oct;6(10):1134-9
11017145
Endocr Rev. 1998 Feb;19(1):18-54
9494779
Endocrinology. 1999 Oct;140(10):4451-8
10499498
Clin Exp Metastasis. 2006;23(1):19-31
16715352
J Virol. 1998 Dec;72(12):9706-13
9811704
Gynecol Oncol. 2007 Apr;105(1):113-21
17173958
Endocrinology. 2000 Sep;141(9):3478-84
10965921
Clin Exp Metastasis. 2008;25(2):119-29
18064531
Clin Cancer Res. 2001 Jan;7(1):120-6
11205899
Mol Cancer Ther. 2008 Jul;7(7):2160-9
18606716
Gene Ther. 2001 Aug;8(15):1142-8
11509944
Endocrinology. 1989 Oct;125(4):1805-13
2676473
Cancer Res. 2004 May 15;64(10):3479-85
15150101
Gene Ther. 2001 Jan;8(2):89-98
11313778
Clin Cancer Res. 2004 Dec 15;10(24):8697-703
15623655
J Natl Cancer Inst. 2006 Feb 1;98(3):203-14
16449680
J Clin Invest. 1996 Oct 1;98(7):1544-9
8833902
Cancer Gene Ther. 2009 Jun;16(6):473-88
19197323
Cancer Res. 2003 Mar 1;63(5):912-6
12615702
Endocr Rev. 1999 Jun;20(3):345-57
10368775
Prostate. 2002 Jun 1;52(1):20-33
11992617